News

Vitrolife in IVF technology deal
Enlarge image

BusinessHungarySweden

Vitrolife in IVF technology deal

02.07.2012 - Cell cultivation company Vitrolife announced it will acquire Hungarian Cryo Management Ltd, a specialist in time-lapse embryo monitoring for IVF.

Gothenburg – The purchase sum is €5m, and could be increased to €9m upon the fulfilment of defined objectives primarily related to sales during the period 2013 to 2015. Through the acquisition, Vitrolife gains access to a product portfolio in the form of time-lapse products for IVF and increased knowledge within IVF technology and embryo development.

The fixed purchase sum is financed by a corporate acquisition loan of €3m and by payment of €2m in newly issued shares or cash. If payment is in shares, this is planned to be carried out after distribution of the subsidiary Xvivo Perfusion AB.  Vitrolife, headquartered in Gothenburg in Sweden, anticipates that the acquisition will have a marginally negative effect on earnings per share for 2012 due to increased marketing activities and transaction expenses but that the business will make a positive contribution as from 2013.  Cryo Management Ltd and its subsidiary Cryo Innovation Ltd are located in Budapest, Hungary. The company was formed in 2005, with 20 employees and budgeted sales of approximately €2m for 2012. The company has developed, produced and marketed time-lapse products, primarily for the IVF market. Its Primo Vision time-lapse technology  takes images of the embryos at short intervals during the cultivation process. The pictures are then played back as a film which is analysed by an embryologist. This method avoids, amongst other things, today’s problem that the sensitive embryo is subjected to stress when being evaluated as the embryo must be taken out of the incubator for assessment. The time-lapse technology also enables the entire development of the embryo to be studied, which gives greater opportunities to choose the most optimal embryo and thereby improve the chances of pregnancy.

http://www.european-biotechnology-news.com/news/news/2012-03/vitrolife-in-ivf-technology-deal.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • IMMUPHARMA (UK)26.50 GBP-10.17%
  • DBV TECHNOLOGIES (F)53.40 EUR-5.79%
  • FLAMEL TECHNOLOGIES (F)11.37 USD-4.29%

TOP

  • BIOFRONTERA (D)3.26 EUR39.3%
  • SYNAIRGEN (UK)35.50 GBP36.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)47.10 SEK-22.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1818.9%
  • NICOX (F)8.01 EUR321.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.7%
  • BB BIOTECH (D)44.01 EUR-83.2%
  • CYTOS (CH)0.25 CHF-78.6%

No liability assumed, Date: 05.05.2016